Bio-Techne Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $295.9 million, flat year-over-year on both an organic and reported basis.

Adjusted EPS: $0.46, up 10% year-over-year; GAAP EPS increased to $0.24 from $0.22.

Adjusted Operating Margin: 31.1%, up 100 basis points year-over-year.

Adjusted Gross Margin: 68.5%, down from 70.5% the previous year, attributed to unfavorable product mix.

Operating Cash Flow: $82.4 million, with $5.9 million in net capital expenditures.

Bank Debt: $260 million, down $40 million sequentially.

2Strategic Updates and Business Highlights

Growth Verticals: The company focuses on four strategic growth areas: cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools, which now account for 47% of total revenue.

Cell Therapy: Excluding two major customers with FDA Fast Track designations, cell therapy showed strong growth, with overall GMP reagent demand down over 30% due to these designations.

Geographic Performance: China reported mid-single-digit growth for the third consecutive quarter, while APAC (excluding China) grew nearly 20%.

Product Innovations: Introduced new assays for the Ella platform and launched the Culturex Synthetic Hydrogel for organoid applications, reflecting a commitment to innovation.

3Forward Guidance and Outlook

Q3 Expectations: Anticipated organic growth to be consistent with Q2, with underlying growth expected to be mid-single digits when excluding customer-specific headwinds.

Fiscal Year 2026 Outlook: The company maintains a low single-digit growth outlook for the full year, with expectations for improvement as headwinds from cell therapy customers abate.

Fiscal Year 2027: Positive sentiment around biotech funding and academic budgets suggests potential for stronger growth as the company laps easier comparisons.

4Bad News, Challenges, or Points of Concern

Flat Revenue Growth: Organic revenue growth was flat due to headwinds from timing impacts related to major customers in cell therapy.

Declining Academic Market: The U.S. academic market showed a modest decline, although stabilization is expected with favorable federal funding developments.

Gross Margin Pressure: The decline in gross margin was driven by an unfavorable product mix and lower-margin customer orders in diagnostics.

Emerging Biotech Struggles: Revenue from emerging biotech customers declined mid-single digits, reflecting ongoing funding pressures.

5Notable Q&A Insights

Customer Sentiment: There is optimism regarding improving customer sentiment in biotech, with funding conditions stabilizing and showing signs of recovery.

Cell Therapy Impact: The two major customers' Fast Track designations are expected to create a temporary headwind, with a gradual return to normalized growth anticipated in fiscal 2027.

M&A Strategy: The company remains focused on M&A as a priority for capital allocation, with interest in expanding capabilities in novel antibodies and cell therapy.

AI Integration: Management views AI as a potential tailwind, enabling customers to enhance their R&D productivity and specificity in material needs. Overall, Bio-Techne's Q2 2026 results reflect a stable performance amidst challenging market conditions, with strategic investments and a focus on innovation positioning the company for future growth.